Document:

License Agreement (Fondazione Salvatore Maugeri)

 EXHIBIT 10.13 
  

					
		  		  	 *  Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately
with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

 LICENSE AGREEMENT 

This License Agreement (“Agreement”) is made as of September 26, 2014 (the “Effective Date”) by
and between the Fondazione Salvatore Maugeri, an organization established under the laws of Italy (“FSM”), and Cardiogen Sciences, Inc., a Delaware corporation (“Cardiogen”). Each of FSM and Cardiogen are referred
to herein as “Party” and together as the “Parties.” 
 RECITALS 

WHEREAS, Dr. Silvia Priori and other researchers employed by FSM have identified certain nucleic acid sequences associated with single
mutation arrhythmias that may be useful for the treatment of certain cardiovascular conditions by means of gene therapy; 
 WHEREAS, FSM has
filed patent applications claiming certain methods of treating such conditions by inserting such sequences into cells; and 
 WHEREAS,
Cardiogen desires to obtain a license from FSM to develop and commercialize products based on such methods and related compositions , and certain other sequences related to single mutation arrhythmias that have been or may be identified by or on
behalf of FSM in the future; and 
 WHEREAS, FSM is willing to grant such license to Cardiogen based on the assumption that Cardiogen has
adequate and necessary skills and resources to utilize such methods and related compositions, as well as to develop and commercialize products based thereon, itself or working with or through sublicensees, on the terms and conditions set forth
below. 
 NOW, THEREFORE, in consideration of these premises and the mutual covenants and agreements set forth herein, the sufficiency of
which is hereby acknowledged, the Parties agree as follows: 
 AGREEMENT 

Definitions 

“Affiliate” means any company or entity controlled by, controlling or under common control with a Party. As used in
this Section 1.1, “control” means (a) that an entity or company owns, directly or indirectly, fifty percent (50%) or more of the voting stock of another entity, or (b) that an entity, person or group has the actual
ability to control and direct the management of the entity, whether by contract or otherwise. 
 *Confidential Treatment Requested.

 “Calendar Quarter” means a period of three (3) consecutive months
ending on the last day of March, June, September, or December, respectively. 
 “Calendar Year” means a
twelve (12) month period ending on the last day of December. 
 “Combination Product” means a Product
that includes an Other Component. 
 “Common Stock” means Cardiogen’s common stock, par value $0.0001
per share. 
 “Confidential Information” has the meaning given to such term in Section 0. 

“CPVT” means catecholaminergic polymorphic ventricular tachycardia. 

“Field” means treatment, prevention or amelioration of diseases or conditions in humans or other animals. 

“FSM Existing IP” means (i) those patents and patent applications covering methods of treating recessive CPVT
that are set forth on Exhibit A, (ii) all patent applications filed claiming priority from such patent applications, including divisionals, continuations, continuations-in-part, provisionals, converted provisionals, and continued prosecution
applications, (iii) any and all patents that have issued or in the future issue from the foregoing patent applications, (iv) any and all reissues, re-examinations and extensions (including any supplementary protection certificates and the
like) of the foregoing patents or patent applications, and (v) all international counterparts of any of the foregoing. 

“Fully-Diluted Capitalization” means the number of shares of Common Stock then outstanding, assuming (a) the
exercise and conversion of all outstanding options, warrants and other rights to acquire Cardiogen’s capital stock; (b) the conversion of all shares of outstanding preferred stock of Cardiogen, if any; and (c) the issuance of all
shares of Common Stock reserved but unissued under Cardiogen’s equity incentive plan. 
 “Improvement
IP” means all intellectual property rights in, or claiming or covering, Improvements that are owned or controlled by FSM, including without limitation (i) all patent applications filed claiming Improvements, including divisionals,
continuations, continuations-in-part, provisionals, converted provisionals, and continued prosecution applications, (ii) any and all patents that have issued or in the future issue from the foregoing patent applications, (iii) any and all
reissues, re-examinations and extensions (including any supplementary protection certificates and the like) of the foregoing patents or patent applications, and (iv) all international counterparts of any of the foregoing. 

“Improvements” means inventions, information and technology comprising nucleic acid sequences associated with single
mutation arrhythmias that are discovered or identified by or on behalf of FSM as of or after the Effective Date, as well as methods of making or using such sequences, methods of administering such sequences to cells or tissues, and compositions and
methods necessary or useful to practice the foregoing. Improvements will include without  

  
 2 

 
limitation inventions, information and technology relating to arrhythmogenic syndromes, including without limitation recessive CPVT, dominant CPVT, short QT, dominant LQTS, recessive LQTS,
Brugada, right ventricular cardiomyopathy, lamin A/C cardiomyopathy and dilated cardiomyopathy. For clarity, FSM shall have no obligation to fund research to identify Improvements, and may seek grants from non-profit entities in connection with
FSM’s efforts to discover or identify Improvements. 
 “Information” means any and all information, data,
know-how, processes, manufacturing processes, trade secrets, inventions, discoveries (whether or not patentable), inventions (whether or not patentable), developments, results, techniques (including without limitation manufacturing techniques) and
chemical, physical or biological materials. 
 “Licensed IP” means the FSM Existing IP and the Improvement
IP. 
 “LQTS” means long QT syndromes [*]. 

“Net Sales” means, collectively, the gross invoiced sales price of all Products sold by Cardiogen, or its Affiliates
or Sublicensees, of the Product (each, a “Seller”) to Third Party purchasers after deduction of the following items whether currently in effect or which become effective during the Term as they pertain to the Products, if and to the
extent they are included in the gross invoiced sales price of the Product or otherwise directly incurred by the Seller with respect to the sale of the Product, and not otherwise deducted in computing other amounts hereunder: 

any and all normal and customary trade, prompt payment, cash and quantity discounts, customary allowances actually granted to purchasers of a
Product for returns and recalled Product (including in connection with Product withdrawals, expired Product and Product recalls), chargeback and reporting fees paid to wholesalers and other distributors, allowances to end users participating in
incentive programs, rebates and other credit adjustments based upon shipping discrepancies and order errors; 
 administrative fees to
managed health care organizations; 
 freight expenses for shipping Product in finished package form (including insurance) to such
purchasers, including without limitation the costs of export licenses, shipping, postage and handling charges; 
 any taxes and tariffs or
duties paid, absorbed or allowed that are paid on sales of Product in finished package form, (excluding income taxes); 
 amounts invoiced
for Products that are not paid, to the extent calculated in accordance with generally accepted accounting principles. 
 Sales to a Third
Party distributor of such Product in any given country shall be considered a sale to a Third Party purchaser. Sale or transfer to an Affiliate or Sublicensee for re-sale by such Affiliate or Sublicensee shall not be considered a sale for the purpose
of this provision, but the resale by such Affiliate or Sublicensee to a Third Party shall be a sale for such purposes. 

  

					
		  	3	  	*Confidential Treatment Requested.

 Notwithstanding the foregoing, in the event a Product is sold in a country in the Territory as a
Combination Product, Net Sales of the Combination Product will be calculated as follows: 
 (i) If the Product (without such Other Component)
and the Other Component(s) contained in the Combination Product each are sold separately in such country, Net Sales will be calculated by multiplying the total Net Sales (as described above) of the Combination Product by the fraction A/(A+B), where
A is the average gross selling price in such country of the Product (without such Other Component) sold separately in the same formulation and dosage, and B is the sum of the average gross selling prices in such country of such Other Component(s)
sold separately in the same formulation and dosage, during the applicable Calendar Year. 
 (ii) If the Product (without such Other
Component) is sold independently of the Other Component(s) contained in the Combination Product in such country, but the average gross selling price of such Other Component(s) in such country cannot be determined, Net Sales will be calculated by
multiplying the total Net Sales (as described above) of the Combination Product by the fraction NC where A is the average gross selling price in such country of such Product (without such Other Component) sold independently and C is the average
gross selling price in such country of the entire Combination Product, during the applicable Calendar Year. 
 (iii) If the Other
Component(s) contained in the Combination Product are sold independently of the Product (without such Other Component) in such country, but the average gross selling price of such Product (without such Other Component) in such country cannot be
determined, Net Sales will be calculated by multiplying the total Net Sales (as described above) of the Combination Product by the fraction (1-(B/C)), where B is the average gross selling price in such country of such Other Component(s) and C is the
average gross selling price in such country of the entire Combination Product, during the applicable Calendar Year. 
 (iv) If the Product
(without such Other Component) contained in the Combination Product and Other Component(s) contained in the Combination Product are not sold separately in such country, or if they are sold separately but the average gross selling price of neither
such Product (without such Other Component) nor such Other Component(s) can be determined in such country, Net Sales of the Combination Product in such country will be calculated by mutual agreement of the Parties. 

“Other Component” means any therapeutically active pharmaceutical ingredient that is not covered or claimed by, or is
not included in, the Licensed IP or Improvements, or any proprietary delivery device or other proprietary delivery means (including without limitation a viral vector). 

“Patent” means any and all patents, inventor certificates, patent applications (including provisionals, divisionals,
continuations and continuations in part), patents issuing from any applications, reissues, reexaminations, extensions and supplemental protection certificates, and all foreign cognates of the foregoing. 

  
 4 

 “Product” means any product, the manufacture, use or sale of which
(i) would infringe, but for a license thereunder, a Valid Claim of a patent application (determined as if such application were then issued) and/or a patent included in the FSM Existing IP or the Improvement IP, or (ii) would use or
incorporate, or is based on, Improvements or the inventions claimed in the FSM Existing IP or the Improvement IP. 

“Regulatory Authority” means any national, supra-national, regional, state or local regulatory agency, department,
bureau, commission, council or other governmental entity, with jurisdiction over the manufacture, distribution, use or sale of Product in the applicable jurisdiction in the Territory. 

“Seller” has the meaning given to such term in Section 1.16. 

“Sublicensee” means any Third Party to whom Cardiogen has granted (a) a sublicense under the FSM Existing IP and
Improvement IP, (b) the right to distribute or sell any Product, if such Third Party is obligated to make payments to Cardiogen in exchange for the grant of such rights (and is not an individual person who is a sales representative of
Cardiogen), (c) a covenant not to sue or other legal right having an effect similar to either of (a) or (b), or (d) an option for either of (a) or (b).  

“Sublicense” shall be interpreted accordingly. For the avoidance of doubt, a distributor shall not be considered a
Sublicensee. 
 “Term” has the meaning given to such term in Section 8.1. 

“Territory” means worldwide. 

“Third Party” means any Party other than FSM or Cardiogen or their respective Affiliates. 

“Valid Claim” means a claim of an issued and unexpired Patent that (a) has not been revoked, declared
unenforceable or unpatentable, or held invalid by a court or governmental agency of competent jurisdiction that is unappealable or unappealed within the time allowed for appeal, (b) has not been admitted to be or rendered invalid or
unenforceable through reissues, disclaimer or otherwise, and (c) has not been finally cancelled, withdrawn, abandoned or rejected by any governmental agency of competent jurisdiction. 

Development and Commercialization 

Development. Cardiogen shall conduct and be solely responsible for all development of the Products in the Field in the Territory, at
Cardiogen’s expense. Cardiogen shall be solely responsible for all correspondence with Regulatory Authorities regarding the Products in the Field in the Territory, and all activities associated therewith, at Cardiogen’s sole responsibility
and expense. Within [*] after the end of each Calendar Year, Cardiogen shall provide FSM with an annual written report summarizing Cardiogen’s development activities under this Agreement and the development activities of its Affiliates and
Sublicensees. 
 Manufacturing; Commercialization. Cardiogen shall be solely responsible for, and shall have sole responsibility and
decision-making authority over all aspects of all manufacturing and commercial activities for the Product in the Field in the Territory, including the  

  

					
		  	5	  	*Confidential Treatment Requested.

 
manufacturing, supply, marketing, promotion, sales and distribution of the Products in the Field in the Territory, at Cardiogen’s expense. Within [*] after the end of each Calendar Year
following the first commercial sale of Products in the Territory, Cardiogen shall provide FSM with an annual written report summarizing the commercial activities of Cardiogen, its Affiliates and Sublicensees under this Agreement. Further, within [*]
following the end of each Calendar Year following the first commercial sale of a Product in the Territory hereunder, Cardiogen shall provide FSM with a separate written report of Net Sales of all Products during such Calendar Year. 

Disclosure of Improvements. From time to time, as long as this Agreement is in full force and effect and Cardiogen is fully performing
its obligations thereunder, FSM would transfer to Cardiogen Information regarding the Improvements as necessary to enable Cardiogen to practice the license set forth above, including with respect to the manufacture and commercialization of the
Products, under the terms and conditions embodied in the Agreement. 
 Diligence by Cardiogen. Cardiogen shall use
commercially reasonable efforts to develop, and after receiving regulatory approval for Products in a given country, commercialize such Products in such country, using efforts that are in no event less than those Cardiogen uses to develop its other
products of similar nature and market potential. Without limiting the foregoing, Cardiogen would obtain a license or right to use one or more viral vectors useful to deliver Products on or prior to the first anniversary of the Effective Date. If FSM
in good faith believes that Cardiogen is in material breach of its obligations under this Section 2.4, FSM shall promptly notify Cardiogen of such breach in writing. Cardiogen shall have [*] thereafter to cure any such material breach (or, if
such breach is not curable within [*], Cardiogen shall commence promptly good faith efforts to cure such breach, develop in consultation with FSM a reasonable plan and timeline for curing such material breach, and shall continue to use diligent
efforts to cure such material breach in a timely manner (and in any event will cure such material breach within [*]). If Cardiogen fails to timely cure its material breach within such [*] period, or to comply with the foregoing parenthetical if
applicable (including without limitation to timely cure within [*] its material breach that is not curable within [*]), then FSM may terminate this Agreement immediately by written notice as set forth in Section 8.3(a) (without regard to any
other cure periods contained in such Section 8.3(a)). 
 License Grant 

License Grant to Cardiogen. Subject to and conditioned upon the terms and conditions of this Agreement, FSM hereby grants to Cardiogen:
(a) an exclusive license (with the right to sublicense, through one or multiple tiers) under FSM’s rights in the FSM Existing IP, Improvements and the Improvement IP, to develop, use, sell, offer for sale, market, export and import
Products in the Field in the Territory. 
 Sublicenses by Cardiogen. Any sublicense shall be consistent with and subject to
the terms and conditions of this Agreement, and shall incorporate terms and conditions sufficient to enable Cardiogen to fully comply with this Agreement. Cardiogen shall be and remain jointly responsible for the performance and actions of
Sublicensees as if such performance or actions were performed by Cardiogen under this Agreement, including without limitation those actions which, if performed by Cardiogen, would be a breach of Cardiogen’s obligations under this Agreement.

  

					
		  	6	  	*Confidential Treatment Requested.

 Compensation 

Upfront Fee. As an upfront fee, Cardiogen shall issue to FSM 425,000 shares of Cardiogen’s Common Stock (the
“Shares”), which as of immediately prior to the Effective Date represents [*]% of the issued and outstanding shares of Common Stock and [*]% of the Fully-Diluted Capitalization. The Shares shall be fully vested as of the date of
issuance. The issuance of the Shares shall be subject to the terms and conditions of a definitive stock purchase agreement to be entered into between Cardiogen and FSM. 

Royalties. 
 Subject to Sections 4.2(b)
and 4.3, Cardiogen shall pay FSM royalties equal to [*] percent ([*]%) of aggregate annual Net Sales of Products, on a country by country and Product by Product basis, in each country in which Product is covered by a Valid Claim of a patent included
in the Licensed IP. The royalties due to FSM pursuant to this Section 4.2(a) shall be payable on a country-by-country and Product-by-Product basis until the expiration of the last Valid Claim covering such Product in such country. 

If, in connection with the manufacture, use, or commercialization of a Product, Cardiogen is obligated to make payments to any Third Parties,
then Cardiogen may offset against the royalty owed to FSM for that Product [*] percent ([*]%) of those amounts payable to such Third Parties, provided that in no event would any such offsets result in reducing royalties due to FSM pursuant to
Section 4.2(a) to less than [*] percent ([*]%) of annual aggregate Net Sales of Products by Cardiogen, its Affiliates and Sublicensees. 

Sales of Product Subject to Royalties. Sales of Product between Cardiogen, its Affiliates, and Sublicensees shall not be subject to
royalties hereunder. Royalties shall be calculated on Cardiogen’s, its Affiliates’ and Sublicensees’ sales of the Products to a Third Party. Royalties shall be payable only once for any given sale of Product For purposes of
determining Net Sales, the Product shall be deemed to be sold when invoiced. Net Sales shall not include, and no royalties shall be payable on, transfers of Products that are used as samples or in clinical trials or other transfers or dispositions
for pre-clinical, clinical or regulatory purposes. 
 Royalty Payments. Royalties due pursuant to Section 4.2 shall be
payable [*]. Cardiogen shall delivery a written report to FSM within [*] after the end of each Calendar Quarter that shows, with respect to each country and each Product, the sales volume, gross sales amount, Net Sales calculated pursuant to
Section 1.16 and the exchange rate for each currency. 
 Records Retention, Audit. 

Records Retention. Cardiogen shall, and shall cause its Affiliates and Sublicensees to, keep complete and accurate records or books of
account in accordance with United States generally accepted accounting principles showing the information that is necessary for the accurate determination of the royalties due hereunder with respect to the sale of such Product. Such books and
records shall be retained by Cardiogen, its Affiliates and Sublicensees for [*] after the end of the period to which such books and records pertain. Cardiogen shall require its Sublicensees to report to Cardiogen their calculations of Net Sales of
Products to Cardiogen in a manner consistent with this Agreement. 

  

					
		  	7	  	*Confidential Treatment Requested.

 Audit. Upon the written request of FSM, Cardiogen shall, and shall cause its Affiliates
to, permit a certified public accountant associated with an independent accounting firm designated by FSM and reasonably acceptable to Cardiogen to inspect, during regular business hours and no more than [*] and going back no more than [*] preceding
the current year, all or any part of Cardiogen’s and/or of the Affiliate’ s and/or the Sublicensee’s records and books necessary to check the accuracy of the royalties paid. The accounting firm shall enter into appropriate obligations
with Cardiogen to treat all information it receives during its inspection in confidence. The accounting firm shall disclose to FSM if applicable) and Cardiogen only whether the royalty reports are correct and details concerning any discrepancies,
but no other information shall be disclosed to FSM. The cost of such review, including the charges of any accounting firm, shall be paid by FSM, except that if the royalties have been understated by more than [*] percent ([*]%), the costs shall be
paid by Cardiogen. 
 Mode of Payment. All payments set forth in this Article shall be remitted by wire transfer to the following
bank account of FSM or such other account as FSM may designate in writing to Cardiogen: 
 Bank name: 

Bank address: 
 Account name: 

Account number: 

Currency. All amounts set forth in this Agreement are in U.S. Dollars and all payments required under this Agreement shall be made in
U.S. Dollars. Net Sales in currencies other than U.S. Dollars shall be converted to U.S. Dollars using the actual quarter end exchange rate for such month for converting the applicable currency into U.S. Dollars, as such rate is reported in the Wall
Street Journal. The currency conversion method used by Cardiogen shall be subject to audit by FSM as provided in Section 4.5. 

Interest on Late Payment. Any amounts not paid by Cardiogen when due shall be subject to interest from and including the date payment
is due, through and including the actual date of payment by Cardiogen, at a rate equal to [*]. 
 Taxes. The royalties and
other payments payable by Cardiogen to FSM pursuant to this Agreement (“Payments”) shall not be reduced on account of any taxes unless required by applicable law. Each Party shall be responsible for paying any and all taxes (other
than withholding taxes required to be paid under this Agreement by Cardiogen) levied on account of, or measured in whole or in part by reference to, any income it receives. Each Party shall be responsible for any sales taxes or similar taxes imposed
on any goods or services provided to it. If Cardiogen is required to withhold taxes for any Payment by virtue of the statutes, laws, codes or governmental regulations of a country in which the Product is sold, then Cardiogen will make such payment
of withholding taxes. Any withholding tax so paid by Cardiogen shall be deducted from the gross amount due to FSM, so that the amount paid FSM is net of such withholding tax.  

  

					
		  	8	  	*Confidential Treatment Requested.

 
Cardiogen shall provide FSM with a statement of such withholding tax and the original copy of the tax receipt or tax certificate for the withholding tax paid. Cardiogen shall fully cooperate with
FSM, and provide any assistance and documentation necessary or helpful to secure a lower rate of withholding tax under any applicable tax treaties. Cardiogen also agrees to provide FSM with such assistance as may be reasonably requested by FSM to
enable FSM to claim a refund and/or credit for such withholding tax. Cardiogen shall indemnify FSM for all claims and liability arising from Cardiogen’s, its Affiliates or Sublicensee’s failure to support or pay any such withholding taxes,
including customs, duties, levies, tariffs or similar charges and not arising from any inaccurate or incomplete information provided by FSM with respect thereto. 

Intellectual Property. 
 Ownership of
Licensed IP and Improvements; Disclosure. Notwithstanding anything to the contrary in this Agreement, as between the Parties, FSM shall remain the sole owner of the Licensed IP and the Improvements. FSM shall notify Cardiogen in writing promptly
after becoming aware of any patentable Improvement. 
 Patent Applications and Patents within the Licensed IP. 

Prosecution and Maintenance. Cardiogen would have the first right to file, prosecute and maintain all patent applications and patents
included in the FSM Existing IP and the Improvement IP, in consultation with and subject to the consent of FSM. Prior to the closing of Cardiogen’s Series A financing, FSM shall reimburse all costs of such activities, and after such closing
occurs, such activities shall be conducted at Cardiogen’s expense. FSM would have a backup right to file, prosecute and maintain such patent applications and patents if Cardiogen decided not to do so. Cardiogen would have the right to decline
to file, prosecute and maintain any and all patent applications and patents licensed to it pursuant to the Agreement, by written notice to FSM at least [*] before any applicable filing or response deadline. If FSM receives any such notice from
Cardiogen, such patent application or patent would be licensed to Cardiogen only on a nonexclusive basis. 
 Infringement By Third
Parties. 
 Notification; Process. Cardiogen and FSM shall each promptly notify the other in writing if it learns of any
actual, alleged or threatened infringement or violation of patent applications and patents within the FSM Existing IP and Improvement IP by a Third Party in the Territory. Cardiogen would have the first right to enforce patents included in the FSM
Existing IP and Improvement IP against infringement arising from the development, manufacture or commercialization of products competitive with a Product in the Field in the Territory, at Cardiogen’s sole expense, in consultation with FSM.

 If Cardiogen does not initiate an infringement action or otherwise abate any such actual, alleged or threatened Third Party
infringement of patent applications and patents within the FSM Existing IP and Improvement IP in the Field in the Territory within [*] (or shorter time if required by applicable law) of the later of (i) receiving notification from FSM under
this Section 5.3 of such infringement, (ii) sending notice to FSM under this Section 5.3 of such infringement, or (iii) a written request from FSM to take action with respect to such infringement, or if such 

  

					
		  	9	  	*Confidential Treatment Requested.

 
infringement is outside the scope of Cardiogen’s first right to take action as provided above, then FSM shall have the right, but not the obligation, at its own expense, to bring suit (or
take other appropriate legal action) against any such actual, alleged or threatened infringement of patent applications and patents within the FSM Existing IP and Improvement IP by a Third Party in the Field in the Territory, including the defense
and settlement thereof (subject to Section 5.4 below). 
 In the event either Party brings an infringement action related to patent
applications and patents within the FSM Existing IP and Improvement IP, the other Party shall provide reasonable assistance (at the expense of the Party bringing such infringement action) and authority to file and bring the action, including, if
required to bring such action, being joined as a party plaintiff; provided, however, that neither Party shall be required to transfer any right, title or interest in or to any of its property to the other Party or a Third Party to confer standing on
a Party hereunder. In addition, if either Party brings an infringement action hereunder, the other Party shall have the right to be represented separately in such action by counsel of its own choice, at its own expense. 

Recoveries. Any recovery realized as a result of such suit, claim or action or related settlement shall first be applied to reimburse
the costs and expenses of the Party initiating the action in connection with such action, and then (to the extent not already reimbursed by the initiating Party) to reimburse such costs and expenses of the other Party, and then any remaining amounts
shall be split as follows: (i) if any portion of any such remaining amounts represents recoveries in relation to infringement other than infringement in the Field in the Territory, such portion shall be allocated to FSM; (ii) if Cardiogen
is the initiating party, then the rest of the remaining recovery shall be allocated to FSM in an amount equal to the royalty that would have been payable to FSM under Section 4.2 if Cardiogen had made Net Sales equivalent to the actual sales
that underlie the remaining recovery, with the remaining portion of the remaining recovery being allocated to Cardiogen. 

Settlements. Neither Party may enter into any settlement or consent judgment or other voluntary final disposition of a suit under this
Article without the prior written consent of the other Party, such consent not to be unreasonably withheld, delayed or conditioned. 

Confidentiality. 
 Treatment of
Confidential Information. A Party receiving or gaining access to Confidential Information, as defined below, (the “Receiving Party”) of the other Party (the “Disclosing Party”) will (a) maintain in
confidence such Confidential Information to the same extent the Receiving Party maintains its own proprietary information (but at a minimum each Party shall use commercially reasonable efforts), (b) not disclose such Confidential Information to
any Third Party without prior written consent of the Disclosing Party, and (c) not use such Confidential Information for any purpose except those permitted by this Agreement. As used herein, “Confidential Information” shall
mean all Information, and other information and materials, received by the Receiving Party from the Disclosing Party pursuant to this Agreement or designated Confidential Information hereunder. A Party shall have no non-disclosure or non-use
obligations under this Article with respect to any portion of any Confidential Information which: (i) is generally known or available to the public through no act or failure to act on the part of the Receiving Party; or (ii) was known to
the Receiving Party as shown by its written records,  

  
 10 

 
without obligation to keep it confidential, prior to when it was received from the Disclosing Party; or (iii) is subsequently disclosed to the Receiving Party by a Third Party lawfully in
possession thereof without obligation to keep it confidential; or (iv) has been independently developed by the Receiving Party without the aid, application or use of Confidential Information or any other breach of this Article as shown by the
Receiving Party’s written records. 
 Permitted or Required Disclosures. A Party shall have no non-disclosure obligation under
this Article with respect to any portion of Confidential Information which is required by law to be disclosed, but then only to the limited extent of such legally required disclosure; and provided that (a) the Disclosing Party is notified
reasonably in advance of such disclosure by the Receiving Party and (b) the Receiving Party cooperates as reasonably requested with the Disclosing Party in attempting to obtain confidential or other protective treatment of such Confidential
Information. In addition to the foregoing, either Party may disclose Confidential Information of the other Party under this Agreement to the extent such disclosure is reasonably necessary in filing, prosecuting or maintaining Patents, prosecuting or
defending litigation, enforcing rights and/or obligations under this Agreement, or conducting pre-clinical or human clinical testing of Products, in each case consistent with the other terms and conditions of this Agreement. Additionally, each Party
will have the right to disclose the Confidential Information of the other Party as required by applicable laws, rules or regulations or the rules of a securities exchange. 

No Use of Names. Neither Party shall use the name of the other Party for publicity, advertising or any other commercial purposes
without the prior written approval of the other Party, except and solely to the extent required by law, rule or regulation or rules of a securities exchange. 

Terms of the Agreement. The Parties agree that the material terms of this Agreement will be considered Confidential Information of both
Parties. Notwithstanding the foregoing, each Party shall have the right to disclose the material terms of this Agreement in confidence to any bona fide potential or actual counsel, consultant, tax or accounting advisor, investor, Sublicensee (as to
Cardiogen), acquirer, banker or investment banker, provided that such Party shall receive an adequate binder of confidentiality consistent and substantially similar to the terms contained in this Agreement (including this Article). Additionally,
each Party will have the right to disclose the terms of this Agreement as required by applicable laws, rules or regulations or the rules of a securities exchange. 

Survival of Confidentiality. All obligations of confidentiality and non-use imposed upon the Parties under this Agreement shall
continue indefinitely until such time as the information that is subject to such obligations no longer comprises Confidential Information under one of the exceptions set forth in Section 6.1. 

Representations and Warranties. 

Mutual Representations and Warranties. FSM and Cardiogen each represent, warrant and covenant to the other that:(a) it has the authority
and right to enter into and perform this Agreement; (b) its execution, delivery and performance of this Agreement will not conflict in any material fashion with the terms of any other agreement to which it is or becomes a party or 

  
 11 

 
by which it is or becomes bound; (c) it shall comply in all material respects with all laws, rules, regulations and other governmental requirements applicable to its actions under this
Agreement; and (d) no consent of any Third Party is required for either Party to grant the licenses and rights granted to the other Party under this Agreement and/or to perform its obligations hereunder. 

FSM Representations and Warranties. FSM hereby represents and warrants to Cardiogen as of the Effective Date as follows: 

FSM will not during the Term of this Agreement grant any right to any Third Party under the FSM Existing IP, Improvements and Improvement IP
that would conflict with any of the rights granted to Cardiogen under this Agreement; 
 FSM has not received any notices or communications
as of the Effective Date that the development, manufacture, use, sale, exportation or importation of the Licensed IP and/or Product would infringe any intellectual property rights of any Third Party in the Territory. 

FSM has all rights necessary to grant to Cardiogen the rights FSM purports to grant to Cardiogen pursuant to this Agreement. 

Disclaimer of Warranty. Each Party acknowledges that the other Party cannot assure the safety, usefulness or efficacy of any Product
for any use. EXCEPT FOR THE REPRESENTATlONS AND WARRANTIES SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES (AND HEREBY EXPRESSLY DISCLAIMS) ANY WARRANTY CONCERNING ITS PATENT RIGHTS OR INFORMATION LICENSED UNDER THIS AGREEMENT , INCLUDING WITHOUT
LIMITATION THE VALIDITY OR SCOPE OF ITS PATENT RJGHTS OR THAT PRODUCTS WILL BE FREE FROM INFRINGEMENT OF THE PATENT RIGHTS OF THIRD PARTIES. EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES (AND HEREBY
EXPRESSLY DISCLAIMS) ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF ANY TECHNOLOGY COMPOUND, API OR PRODUCT. 

No Consequential Damages. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, INCIDENTAL SPECIAL,
CONSEQUENTIAL OR PUNITIVE DAMAGES INCURRED BY EITHER PARTY UNDER THIS AGREEMENT OR OTHERWISE; HOWEVER, THE FOREGOING SHALL NOT APPLY TO EITHER PARTY’S OBLIGATIONS UNDER SECTION 6 (CONFIDENTIALITY) AND SECTION 9 (INDEMNIFICATION). 

Term and Termination. 
 Term. This
Agreement shall become effective on the Effective Date and shall remain in effect unless earlier terminated as provided in Sections 8.2 or 8.3 below (the “Term”). 

Termination by Cardiogen. Cardiogen may terminate this Agreement in its entirety at any time upon [*] prior written notice to FSM,
subject to Sections 0 and 0 below. 

  

					
		  	12	  	*Confidential Treatment Requested.

 Termination by Either Party. 

Termination for Breach. Except as otherwise provided in Section 2.4 with respect to an alternative cure period, if either Party
believes that the other Party is in material breach of this Agreement, then the non-breaching Party may deliver notice of such breach to the other Party. In such notice the non-breaching Party shall identify
the actions or conduct that such Party would reasonably consider to be an acceptable cure of such material breach. The allegedly breaching Party shall have [*] from such notice to cure such material breach, or [*] from such notice if such breach
consists of a failure to pay any monies due and payable to the other Party hereunder (in each case, the “Cure Period”). If the Party receiving notice of material breach fails to cure such breach (including with respect to any breach
of Cardiogen’s obligations under Section 2.4) within the applicable Cure Period, the Party originally delivering the notice may terminate this Agreement effective immediately on or after the end of the Cure Period by written notice to the
other Party. 
 Termination for Insolvency. Either Party may terminate this Agreement by written notice to the other Party if
such other Party files or institutes any bankruptcy, liquidation or receivership proceedings, or if such other Party makes an assignment of a substantial portion of the assets of such other Party for the benefit of its creditors; provided, however,
that, in the case of any involuntary bankruptcy proceeding such right to terminate shall only become effective if such other Party consents to the involuntary bankruptcy or such proceeding is not dismissed within [*] after the filing thereof. 

Effect of Termination. Except in the case where Cardiogen terminates this Agreement pursuant to Section 8.3(a) for FSM’s
uncured material breach, upon the effective date of any termination of this Agreement, all licenses granted by FSM to Cardiogen pursuant to Article 0 shall automatically terminate and Cardiogen as well as the Affiliate and/or the Sublicensee shall
immediately cease conducting any and all activities under such licenses. 
 Inventory. After any termination of this
Agreement, Cardiogen, its Affiliates and Sublicensees shall be entitled to sell all of their finished inventory of Products in existence on the date of any such termination, subject to payment to FSM of royalties pursuant to Section 4.2 above.
Notwithstanding the foregoing, however, in no event shall Cardiogen, its Affiliates or Sublicensees be entitled to manufacture any new inventory of Products from and after the effective date of such termination. 

Bankruptcy Rights. In the event that this Agreement is terminated or rejected by a Party or its receiver or trustee under applicable
bankruptcy laws due to such Party’s bankruptcy, then all rights and licenses granted under or pursuant to this Agreement by such Party to the other Party are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the
Bankruptcy Code and any similar law or regulation in any other country, licenses of rights to “intellectual property” as defined under Section 101(52) of the Bankruptcy Code. The Parties agree that all intellectual property rights
licensed hereunder, including without limitation any patents or patent applications of a Party in any country covered by the license grants under this Agreement, are part of the “intellectual property” as defined under Section 101(52)
of the Bankruptcy Code subject to the protections afforded the non-terminating Party under Section 365(n) of the Bankruptcy Code, and any similar law or regulation in any other country. 

  

					
		  	13	  	*Confidential Treatment Requested.

 Survival. The following provisions shall survive any termination of this Agreement:
Sections 1, 4.5, 4.9, 5, 6, 7, 8.4, 8.5, 8.6, 8.7, 9 and 11. Termination of this Agreement shall not relieve either Party of any liability which accrued hereunder prior to the effective date of such termination nor preclude either Party from
pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement nor prejudice either Party’s right to obtain performance of any obligation. The remedies provided under this Article are
cumulative, and are not exclusive of other remedies available to a Party in law or equity. 
 Indemnification. 

By Cardiogen. Cardiogen hereby agrees to indemnify, defend and hold harmless FSM and its Affiliates, and their respective officers,
directors, agents and employees (“FSM Indemnitees”) from and against any and all Third Party suits, claims, actions, demands, liabilities, expenses and/or loss, including reasonable legal expenses and attorneys’ fees
(collectively, “Losses”) resulting from (a) the development, marketing, use, manufacture, handling, storage, transport, distribution, sale or other disposition of the Products by Cardiogen, its Affiliates, agents or
Sublicensees; (b) Cardiogen’s breach of any of its obligations, covenants, representations or warranties under this Agreement; and/or (c) the negligence or wrongdoing of Cardiogen and/or any of its Affiliates, Sublicensees, agents,
representatives, consultants and/or employees under this Agreement, except to the extent FSM is obligated to indemnify Cardiogen for such Losses pursuant to Section 0. 

By FSM. FSM hereby agrees to indemnify, defend and hold harmless Cardiogen, its Affiliates, and their respective officers, directors,
agents and employees from and against any and all Losses resulting from: (a) FSM’s breach of any of its obligations, covenants, representations or warranties under this Agreement ; and (b) the negligence or wrongdoing of FSM and/or
any of the FSM Indemnitees under this Agreement ; except to the extent Cardiogen is obligated to indemnify FSM for such Losses pursuant to Section 9.1. 

Notice and Procedures. In all cases where one Party seeks indemnification by the other under this Article, the Party seeking
indemnification shall promptly notify the indemnifying Party of receipt of any claim or lawsuit covered by such indemnification obligation and shall cooperate fully with the indemnifying Party in connection with the investigation and defense of such
claim or lawsuit. The indemnifying Party shall have the right to control the defense, with counsel of its choice, provided that the non-indemnifying Party shall have the right to be represented by advisory counsel at its own expense. The
indemnifying Party shall not settle or dispose of the matter in any manner which could negatively and materially affect the rights or liability of the non-indemnifying Party without the non-indemnifying Party’s prior written consent, which
shall not be unreasonably withheld or delayed. 
 Insurance. 

Coverages. Cardiogen shall obtain and maintain (or shall ensure that its Affiliates and Sublicensees obtain and maintain, as
applicable), at its or their own expense, the following insurance coverages: 

  
 14 

 Clinical Trials Liability. From the date of initiation of the first clinical trial in the
Territory by Cardiogen, its Affiliates or Sublicensees and continuing for the remainder of the Term of this Agreement, coverage insuring against claims for bodily injury and property damage arising out of clinical trials, with coverage and limits
that at a minimum comply with statutory/country requirements where the trials will be performed. 
 General Liability. Within
[*] after the closing of Cardiogen’s Series A financing, and continuing for the remainder of the Term of this Agreement, general liability insurance (including excess liability insurance) insuring against claims arising anywhere in the world,
with cumulative minimum limits of not less than $[*]. 
 Products Liability. Prior to the first distribution of the Product by
Cardiogen, its Affiliates or Sublicensees for any human use, whether clinical, commercial or noncommercial, and continuing for the remainder of the Term of this Agreement products liability insurance insuring against claims arising anywhere in the
world, with initial minimum limits of not less than $[*], with such minimum limits increased to not less than $[*] at the first annual policy renewal subsequent to the first Calendar Year in which Net Sales of Product exceed in the aggregate
$[*]. 
 General. 
 Governing
Law; Arbitration. This Agreement shall be governed by and interpreted in accordance with the substantive laws of the State of New York, U.S.A. without regard to its or any other jurisdiction ‘s choice of law rules that would result in the
application of the laws of any state other than the State of New York, U.S.A. 
 Exclusive Dispute Resolution Mechanism. The
Parties agree that the procedures set forth in this Section 11.1 shall be the exclusive mechanism for resolving any dispute, controversy, or claim (collectively, “Disputes”) between the Parties that may arise from time to time
pursuant to this Agreement relating to any Party’s rights and/or obligations hereunder, or relating to the interpretation or application of this Agreement, that are not resolved through good faith negotiation between the Parties. 

Discussion of Officers. Any Disputes shall be submitted initially by either Party for resolution by the Chief Executive Officer (or
equivalent) of Cardiogen and the (or equivalent) of FSM, who shall meet and discuss such matter within [*] after a Party proposes that such officers meet to discuss such matters. In the event such officers do not resolve such dispute within [*]
after they first meet, then either Party may submit such issue for resolution by binding arbitration in accordance with Section 11.1(c). 

Arbitration. 
 Any arbitration
concerning a Dispute shall be conducted in New York, New York, United States of America unless otherwise agreed to by the Parties in writing. Each and any arbitration shall be administered by the American Arbitration Association (the
“AAA”), and shall be conducted in accordance with the Commercial Arbitration Rules of the AAA (the “Rules”), as such Rules may be amended from time to time. 

  

					
		  	15	  	*Confidential Treatment Requested.

 Within [*] after receipt of an arbitration notice from a Party, the Parties shall attempt in good
faith to agree on a single neutral arbitrator with relevant industry experience at a senior executive level to conduct the arbitration. If the Parties do not agree on a single neutral arbitrator within [*] after receipt of an arbitration notice,
each Party shall select one (1) arbitrator and the two (2) Party-selected arbitrators shall select a third arbitrator with relevant industry experience at a senior executive level to constitute a panel of three (3) arbitrators to
conduct the arbitration in accordance with the Rules. In the event that only one of the Parties selects an arbitrator, then such arbitrator shall be entitled to act as the sole arbitrator to resolve the Dispute or any all unresolved issues subject
to the arbitration. Each and every arbitrator of the arbitration panel conducting the arbitration must and shall agree to render an opinion within [*] after the final hearing before the panel. 

The arbitrators shall permit reasonable discovery and submission of evidence so as to allow the Parties to submit to the arbitrators all
salient facts. The decision or award of the arbitrator(s) shall be final and binding, and may be used as a basis for judgment thereon in any jurisdiction. The arbitrator(s) shall, upon the request of any Party, issue a written opinion of the
findings of fact and conclusions of law and shall deliver a copy to each of the Parties. Each Party shall bear its own costs and attorney’s fees, and the Parties shall equally bear the fees, costs, and expenses of the arbitrator(s) and the
arbitration proceedings; provided, however, that the arbitrator(s) may exercise discretion to award costs, including without limitation attorney’s fees, to the prevailing Party. Without limiting any other remedies that may be available under
applicable law, the arbitrator(s) shall have no authority to award punitive, special, consequential, or any other similar form of damages. 

Notwithstanding anything in this Agreement to the contrary, a Party may seek a temporary restraining order or a preliminary injunction from
any court of competent jurisdiction in order to prevent immediate and irreparable injury, loss, or damage on a provisional basis, pending the decision of the arbitrator(s) on the ultimate merits of any Dispute. 

Notwithstanding anything in this Agreement to the contrary, any and all issues regarding the scope, construction, validity, inventorship and
enforceability of one or more patent applications or patents shall be determined in a court of competent jurisdiction under the local patent laws of the jurisdictions having issued the patent application or patent in question. 

All proceedings and decisions of the arbitrator(s) shall be deemed Confidential Information of each of the Parties, and shall be subject to
Article 6. 
 Assignment. Except as otherwise provided herein, neither this Agreement nor any interest hereunder shall be assignable in part or in
whole by any Party without the prior written consent of the other Party; provided, however, that, subject to the payment obligations of Section 4.2, either Party may assign or transfer its rights and obligations under this Agreement, without
such consent, to an affiliate or a purchaser of all or substantially all of the assigning Party’s stock or assets to which this Agreement relates. This Agreement shall be binding upon the successors and permitted assigns of the Parties. Any
assignment not made in accordance with this Section 11.2 shall be null and void. 

  

					
		  	16	  	*Confidential Treatment Requested.

 Notice. All notices under this Agreement shall be in writing and shall be deemed given upon personal
delivery, facsimile transmission with electronic confirmation of transmission, delivery by internationally- or nationally-recognized courier service, or seven (7) days after sending by certified or registered mail, postage prepaid and return
receipt requested, to the following addresses or facsimile numbers of the respective Parties or such other address or facsimile number as given by proper notice under this Section 11.3: 

 

							
	FSM:	 	 Fondazione Salvatore Maugeri
  

Attention:
 Fax No.:
	 		  	
				
	Cardiogen:	 	 Cardiogen Sciences, Inc.
 Address:

Attention:                        
     
 Fax
No:                                
	 		  	

 Captions and Headings; Construction. The captions and headings used in this Agreement are inserted for convenience
only, do not form a part of this Agreement, and shall not be used in any way to construe or interpret this Agreement. This Agreement has been negotiated by the Parties and shall be interpreted fairly in accordance with its terms and without any
construction in favor of or against any Party. This Agreement shall be deemed to have been drafted by all Parties and, in the event of a dispute, no Party hereto shall be entitled to claim that any provision should be construed against the other
Party by reason of the fact that it was drafted by one particular Party. 
 Entire Agreement; Waiver; Full Force and Effect. This Agreement (and its
Exhibit) sets forth the complete, final and exclusive agreement between the Parties and supersedes and terminates all prior and contemporaneous agreements and understandings between the Parties related to the subject matter addressed herein. No
amendment to, or waiver of right under, this Agreement shall be effective unless in writing signed by authorized representatives of the Parties. If any provision of this Agreement is judicially or administratively determined to be unenforceable, the
provision shall be reformed to most nearly approximate the Parties’ original intent, but otherwise this Agreement shall continue in full force and effect. 

Independent Contractor. Cardiogen’s relationship with FSM shall be that of an independent contractor, and nothing in this Agreement shall be
construed to create a partnership, joint venture, or employer- employee relationship. Cardiogen is not the agent of FSM and is not authorized to make any representation, contract, or commitment on behalf of
FSM. 
 Counterparts. This Agreement may be executed in counterparts (including by facsimile and PDF), each of which, when so executed and delivered,
shall be deemed an original, and all of which counterparts, taken together, shall be deemed an original. 

  
 17 

 Further Actions. Each Party agrees to execute, acknowledge and deliver such further documents and
instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. Each Party hereby appoints the other Party as attorney-in-fact solely to execute and deliver the
foregoing documents and instruments if such other Party, after making reasonable inquiry of the appointing Party, does not obtain them from such appointing Party. 

(signature page follows) 

  
 18 

 IN WITNESS WHEREOF, the Parties hereto have caused their duly authorized representatives to
execute this Agreement as of the Effective Date. 
  

									
	Fondazione Salvatore Maugeri	 		 	Cardiogen Sciences, Inc.
					
	By:	 	 /s/ Luigi Migliavacca
	 		 	By:	 	 /s/ Louis Lange

	Name:	 	LUIGI MIGLIAVACCA	 		 	Name:	 	Louis Lange
	Title:	 	VICE PRESIDENT	 		 	Title:	 	CEO

  
 19 

 Exhibit A 

FSM Existing IP 
 [*] 

  

					
		  		  	*Confidential Treatment Requested.Exclusive License Agreement (University of Florida)

 EXHIBIT 10.14 
  

					
		  		  	 *  Certain confidential information contained in this document, marked by brackets, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

 EXCLUSIVE LICENSE AGREEMENT WITH KNOW-HOW 

Agreement No: A13169 

TABLE OF CONTENTS 
  

					
		  	 Appendix A – Patent Rights and Know-How

Appendix B - Development Plan
 Appendix C Development Report

Appendix D - UFRF Royalty Report
 Appendix E - Milestones
	  	

 This Agreement is effective as of July 28, 2015 (the “Effective Date”) between the University
of Florida Research Foundation, Incorporated (hereinafter called “UFRF”), a nonstock, nonprofit Florida corporation, and Audentes Therapeutics, Inc. (hereinafter called “Licensee”), a Delaware corporation having a principal
address at 101 Montgomery Street, Suite 2650, San Francisco, CA 94104. 
 WHEREAS, Licensee is engaged in business relating to the
development and commercialization of products that can use or incorporate UFRF’s intellectual property rights and has the capability of developing commercial applications of the intellectual property; and 

WHEREAS, UFRF owns inventions that are described below; UFRF is willing to grant a license to Licensee under the Patent Rights (defined in
Section 1.12) and Know-How (as defined in Section 1.5); and Licensee desires a license under them. 
 THEREFORE, the parties agree
as follows: 
 Section 1 Definitions 

1.1 “Affiliate” means: (a) any entity which controls at least fifty percent (50%) of the equity or voting stock of the
Licensee or (b) any entity fifty percent (50%) of whose equity or voting stock is owned or controlled by the Licensee or (c) any entity of which at least fifty percent (50%) of the equity or voting stock is owned or controlled by
the same person or entity owning or controlling at least fifty percent (50%) of Licensee. 
 1.2 “Development Plan” means the
written report summarizing the development activities that are to be undertaken by the Licensee to bring Licensed Products to the market that is attached as Appendix B. 
  

					
		  	 Page
 1
 of 25	  	*Confidential Treatment Requested.

 1.3 “Development Report” means a written account of Licensee’s progress under the
Development Plan that includes at least the information specified on Appendix C. 
 1.4 “Investigator” means Dr. Barry Byrne,
while employed by the University of Florida. 
 1.5 “Know-How” means unpatented technology/information/materials, described in
Exhibit A, to the extent wholly owned and wholly controlled by UFRF. 
 1.6 “Licensed Field” means the treatment of Pompe disease.

 1.7 “Licensed Product” means any product or part thereof, on a country-by-country basis, that (a) is covered in whole or in
part by a Valid Claim of the Patent Rights, in any country in which such product is made, used, exported, imported or sold or (b) is manufactured by using a process which is covered in whole or in part by a Valid Claim of Patent Rights, in any
country in which any such process is used or in which any such product is used, imported or sold, or (c) incorporates, utilizes, or was developed or manufactured utilizing Know-How or using a process developed using Know-How. For the avoidance
of doubt, “covered” includes any product or part thereof, the making, using (including therapeutic use), selling, exporting, or importing of which, absent the license granted herein, would infringe a Valid Claim of the Patent Rights. 

1.8 “Licensed Territory” means worldwide. 

1.9 “Net Sales” means the total dollar amount invoiced on sales of Licensed Product by Licensee or by any Sublicensee, less
promotional discounts allowed in amounts customary in the trade, sales taxes and the following deductions: 
 (i) trade and quantity
discounts off the invoice price, to the extent actually incurred or allowed; 
 (ii) amounts actually credited or allowed for rejections or
returns of Licensed Product; 
 (iii) all rebates, chargebacks, retroactive price reductions and other sales allowances that are actually
allowed or granted, including rebates, reductions and allowances mandated by government; 
 (iv) early payment cash discounts, amounts
written off by reason of uncollectible debt (not to exceed [*]% of Gross Sales, custom duties; and 
 (v) insurance, customs charges,
freight, postage, shipping, handling, and other transportation costs to the extent actually incurred by Licensee or its Sublicensee, as applicable, in shipping Licensed Product to a third party. 

In the case of any sale or other disposal of a Licensed Product between or among Licensee and its Affiliates or Sublicensees for resale, Net
Sales shall be calculated as above only on the value charged or invoiced on the first arm’s-length sale thereafter to an unrelated third party. Any consideration received in exchange for the transfer of Licensed Products for use in clinical
trials, sampling or promotional use, or compassionate use, in each case at or below cost, shall not be included in Net Sales. 

  

					
		  	Page 2 of 25	  	*Confidential Treatment Requested.

 1.10 “Orphan Designation” means a special status granted, under the Orphan Drug Act, to
a drug or biological product to treat a rare disease or condition, 
 1.11 “Patent Challenge” means a formal, written challenge,
brought in any judicial or administrative governmental forum having jurisdiction over the subject matter, to the validity, patentability, and/or enforceability of any claim or claims of the Patent Rights. 

1.12 “Patent Rights” means: 

(a) the patent(s)/patent application(s) identified on Appendix A; 

(b) all United States and foreign patent applications claiming priority to any of the patent(s) and patent application(s)
identified in Appendix A; and 
 (c) all patents issuing from the patent applications identified in Subsections 1.12(a) and
1.12(b), including, letters patent, patents of addition, divisionals, continuations of any such patent application to the extent the claims are directed to subject matter specifically described and fully supported in the patent application(s)
identified on Appendix A, and all reissues, re-examinations, extensions, restorations, and supplementary protection certificates. 
 1.13
“Sublicense” means the agreement to grant to, or the agreement not to assert against, a third party any of the rights granted to Licensee under Section 2.1. An agreement that is described in this definition is a Sublicense whether or
not it is called a “sublicense” and whether or not it is included in a stand-alone document or is part of a broader collaboration, development, or joint venture agreement or arrangement, but shall not include any wholesaler or distributor
agreement for the sale of Licensed Product (even if such wholesaler or distributor is granted a right or license to sell Licensed Product) or any contract manufacturing organization or other third party that manufactures Licensed Product on behalf
of Licensee. 
 1.14 “Sublicensee” means any third party that is granted a Sublicense. 

1.15 “Valid Claim” means (a) a claim of an issued patent included within the Patent Rights, in any country that (i) has not
been disclaimed; (ii) has not been cancelled or superseded, or if cancelled or superseded, has been reinstated, or (iii) has not been revoked, held invalid, or otherwise declared unenforceable or not allowable by a tribunal or patent
authority of competent jurisdiction over such claim in such country from which no further appeal has or may be taken; or (b) a pending claim in the Patent Rights until June 19, 2019.

1.16 “Vector Plasmid” means the physical materials described under the Vector Plasmid section in Appendix A, which describe a [*].

  

					
		  	Page 3 of 25	  	*Confidential Treatment Requested.

 Section 2 Grant 

2.1 Patent Rights. In return for the royalties and other payments described in Section 4, UFRF hereby grants to Licensee a
royalty-bearing, exclusive license: 
  

	 	(i)	to use the Vector Plasmid in the Licensed Field and Licensed Territory to make, have made, use, sell, have sold, import, and export Licensed Products; and 

 

	 	(ii)	under the Patent Rights in the Licensed Field and Licensed Territory to make, have made, use, sell, have sold, import, and export Licensed Products. 

2.2 Know-How. In return for the royalties and other payments described in Section 4, UFRF hereby grants to Licensee a
royalty-bearing, non-exclusive (except as pertains to the Vector Plasmid, where such license shall be exclusive) license under UFRF’s rights to the Know-How in the Licensed Field and Licensed Territory to make, have made, use, sell, have sold,
import, and export Licensed Products. 
 2.3 Sublicense Rights. 

(a) Licensee may grant written Sublicenses to third parties through multiple tiers only if Licensee is in compliance with the
diligence obligations in Section 3. However, Licensee shall notify UFRF of the initiation of license negotiations with all potential Sublicensees. Any agreement granting a Sublicense shall state that the Sublicense is subject to the terms of
this Agreement. Licensee has the same responsibility for the activities of any Sublicensee under any Sublicense as if the activities were directly those of Licensee. Licensee shall also include provisions in all Sublicenses consistent with
Section 2.4. 
 (b) UFRF has right to receive copies of Sublicenses subject to the ability to redact confidential
information of the Sublicensee that is not reasonably necessary for UFRF to confirm the compliance of the Sublicense with this Agreement (hereinafter “Redacted Sublicense”). Licensee shall provide UFRF with a final copy of each Redacted
Sublicense within [*] after execution and will include in each Development Report submitted to UFRF hereunder and each royalty report submitted to UFRF under Section 6.4(c), as applicable, information concerning reports received by Licensee
from its Sublicensees regarding development of Licensed Products and payments under the Sublicense agreements. Failure of Licensee to provide UFRF with copies of each Redacted Sublicense agreement within [*] after execution of the Sublicense
agreement is a material breach of this Agreement. 
 2.4 Patent Challenge. If Licensee or any of its Affiliates brings a Patent
Challenge against UFRF, or Licensee or any of its Affiliates actively assists another party in bringing a Patent Challenge against UFRF (except as required under a court order or subpoena), and UFRF does not terminate this Agreement pursuant to
Section 9.4, then: (i) if the Patent Challenge is successful, Licensee may not thereby be entitled to recoup any consideration, including royalties, paid to UFRF during the period of challenge; and (ii) if the Patent Challenge is
unsuccessful, Licensee shall reimburse UFRF for all reasonable legal fees and expenses incurred in its defense against the Patent Challenge. 

2.5 Retained Rights. UFRF reserves to itself and the University of Florida, and their not-for-profit academic collaborators, the right
under the Patent Rights and Know-How to make, have made, develop, import and use Licensed Products solely for their internal not-for-profit research, clinical care (including, but not limited to patient care at Shands Teaching Hospital and 

  

					
		  	Page 4 of 25	  	*Confidential Treatment Requested.

 
University of Florida patient care facilities), and educational purposes and for all applicable governmental requirements and guidelines governing the transfer of materials, provided that the
reservation of rights does not permit the use of the Vector Plasmid in human clinical trials. 
 2.6 Un-Addressed Markets or
Territories. UFRF would like licensees to address unmet needs, such as those of neglected patient populations or geographic areas, giving particular attention to improved therapeutics, diagnostics and agricultural technologies for the developing
worlds. If Licensee is unable or unwilling to serve or develop a potential market or market territory for which there is a company willing to be a Sublicensee, Licensee will, at UFRF’s request, negotiate in good faith a Sublicense with any such
Sublicensee. 
 Section 3 Diligence Obligations 

3.1 Development. Licensee agrees and warrants that: 

(a) it has or will obtain the expertise necessary to evaluate independently the inventions of the Patent Rights and Know-How;

 (b) it will establish and actively and diligently pursue the Development Plan (Appendix B) to the end that inventions of
the Patent Rights and Know-How will be utilized to provide Licensed Products for sale in the retail market within the Licensed Field; 

(c) it will use commercially reasonable efforts to market and commercialize at least one Licensed Product for which regulatory
approval has been obtained; 
 (d) until the date of first commercial sale of the first Licensed Product, it will supply UFRF
with a written Development Report annually [*] after the end of each calendar year; 
 (e) Licensee and Sublicensee(s) shall
apply patent markings that meet all requirements of United States law, 35 U.S.C. §287, with respect to all Licensed Products; and 

(f) [*] before commencement of manufacturing of commercial production of the first Licensed Product, Licensee will include in
the Development Report specifics of planned manufacturing or production. 
 3.2 First Commercial Sale; Milestones. 

(a) Licensee agrees that the first commercial sale of Licensed Products to the retail customer shall occur on or before [*] or
UFRF may terminate the Agreement pursuant to Section 9.3 unless such date is extended pursuant to Section 3.2(b). In addition, if Licensee fails to meet the milestones shown in Appendix E, UFRF may terminate the Agreement pursuant
to Section 9.3 unless such date is extended pursuant to Section 3.2(b). Licensee shall notify UFRF in writing as each milestone is met. 

  

					
		  	Page 5 of 25	  	*Confidential Treatment Requested.

 (b) If Licensee requests an extension of any milestones or due dates set forth in
Section 3.2(a) (i.e., December 31, 2024) or in Appendix E, UFRF shall consider the requests in good faith. Licensee shall make extension requests in writing at least [*] prior to the required due dates, fully describing
Licensee’s diligent efforts to achieve the milestone. Upon granting extension requests, UFRF and Licensee shall negotiate the terms of extensions in good faith. Without limiting the foregoing, in the event that Audentes, within [*] from the
effective date reasonably believes that the dates referred to in Section 3.2(a) (i.e., [*] for first commercial sale and the dates set forth in Appendix E) shall be extended, Audentes shall provide to UFRF a reasonable justification for such
extension, and UFRF shall not unreasonably reject any such request. 
 3.3 Clinical Trials. Licensee will notify UFRF prior to
commencing any clinical trials at the University of Florida or its affiliated medical facilities. Licensee will provide funding to support [*], described in Exhibit A, which will be conducted at the University of Florida. Audentes will be the
sponsor of the investigational new drug application (IND). Conduct of any clinical trial at the University will be subject to all University Policies then in effect. 

Section 4 Payments 
 4.1
License Issue Fee. Licensee shall pay to UFRF a non-refundable license issue fee of [*] dollars ($[*]) within [*] of the Effective Date. 

4.2 Annual License Maintenance Fee. Licensee shall pay an annual license maintenance fee of [*] dollars ($[*]) each year on the
anniversary of the Effective Date of this Agreement. The annual license maintenance fee is payable until the first commercial sale of a Licensed Product, after which time minimum royalties instead of the annual license maintenance fee are due. 

4.3 Left Intentionally Blank. 

4.4 Royalty on Licensed Products. Licensee shall pay UFRF earned royalties calculated as a percentage of Net Sales during the Royalty
Term. Earned royalties are earned as of the earlier of the date the Licensed Product is actually sold and paid for and the date an invoice is sent by Licensee or its Sublicensee(s). Licensee shall pay to UFRF royalties as follows during the Royalty
Term: 
 (a) [*] percent ([*] %) for Net Sales of Licensed Products that are not included in Section 4.4(b). 

(b) [*] percent ([*]%) for Net Sales of Licensed Products that are not covered by a Valid Claim, and respecting which there is
no Orphan Designation exclusivity in the country of sale. 
 Within [*] after the end of each calendar quarter ending on
March 31, June 30, September 30 or December 31, Licensee shall pay amounts owing to UFRF under this Section 4.4 in excess of the amount of minimum royalties paid pursuant to Section 4.5. 

  

					
		  	Page 6 of 25	  	*Confidential Treatment Requested.

 For purposes of this Agreement, “Royalty Term” shall mean the period commencing on the Effective Date
and ending, on a country-by-country basis, on the later of (a) the last to expire of the Valid Claims in the Patent Rights in each country and (b) [*] from the first commercial sale of a Licensed Product in each country in which the
Licensed Product is sold. 
 4.5 Minimum Royalty. 

(a) Beginning in the calendar year of first commercial sale of a Licensed Product, Licensee shall pay UFRF minimum royalty
payments as follows. 
  

			
	 Payment
	  	 Year

	   $[*]
	  	[*]
	   $[*]
	  	[*]
	   $[*]
	  	[*]

 (b) Notwithstanding the table in Section 4.5(a): (i) The first minimum royalty
payment of $[*] is due on [*] or, if the target date for first commercial sale (i.e., [*]) is extended pursuant to Section 3.2(b) to a date later than [*], on [*] of the calendar year in which such extended date will occur; and (ii) the
Licensee shall pay each subsequent minimum royalty payment in advance on an annual basis on or before [*] for each year after the first minimum royalty payment is due, during the term of this Agreement. Minimum royalties apply to earned royalties on
a calendar year basis; Net Sales that are made during a prior or subsequent calendar year have no effect on the annual minimum royalty due to UFRF for other than the same calendar year in which the royalties were earned. 

4.6 Milestone Payments. 

Licensee shall pay UFRF milestone payments within [*] of the first achievement of each milestone for the first Two Indications as follows: 

 

			
	 Milestone
	  	 Payment

	     [*]
	  	$[*]
	     [*]
	  	$[*]
	     [*]
	  	$[*]
	     [*]
	  	$[*]

 “Two Indications” means the following indications for a Licensed Product: [*]. 

4.7 Sublicense Fees. 

(a) With respect to Sublicenses granted by Licensee or by a Sublicensee under Section 2.3(a), Licensee shall pay to UFRF
an amount equal to what Licensee would have been required to pay under Section 4.4 had Licensee sold the Licensed Products that are sold by a Sublicensee. 

  

					
		  	Page 7 of 25	  	 *Confidential Treatment Requested.

 (b) If Licensee receives any fees or payments in consideration for any rights
granted under a Sublicense (e.g., upfront or milestone payments) that are not based directly on the amount or value of Licensed Products sold by the Sublicensee, then Licensee shall pay UFRF within [*] of receipt pursuant to Sublicenses entered into
during the time periods indicated below: 
  

			
	 [*]%
	  	[*]
	 [*]%
	  	[*]
	 [*]%
	  	[*]
	 [*]%
	  	[*]

 (c) Licensee may not receive from Sublicensees anything of value in lieu of cash payments in
consideration for any Sublicense under this Agreement without the express prior written permission of UFRF, which permission UFRF may not unreasonably withheld. 

Section 5 Warranties and Disclaimers of UFRF. 

5.1 UFRF represents that its employees have assigned or are obligated to assign to UFRF their entire right, title, and interest in the Patent
Rights and Know-How and that it has authority to grant the rights and licenses set forth in this Agreement. However, nothing in this Agreement is: 

(a) a warranty or representation by UFRF of the validity or scope of any right included in the Patent Rights; 

(b) a warranty or representation that anything made, used, sold or otherwise disposed of under the license granted in this
Agreement does not infringe patents or other rights of third parties; 
 (c) an obligation to bring or prosecute actions or
suits against third parties for infringement of Patent Rights; 
 (d) an obligation to furnish know-how or services other
than those specified in this Agreement; or 
 (e) a warranty or representation by UFRF that it will not grant licenses to
others to make, use or sell products not covered by the claims of the Patent Rights which may be similar or compete with products made or sold by Licensee. 

5.2 EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, UFRF MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER
EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND VALIDITY OF PATENT RIGHTS CLAIMS, ISSUED OR PENDING. UFRF ASSUMES NO RESPONSIBILITIES WHATSOEVER WITH RESPECT TO USE, SALE, OR
OTHER DISPOSITION BY LICENSEE, ITS SUBLICENSEE(S), OR THEIR VENDEES OR OTHER 

  

					
		  	Page 8 of 25	  	*Confidential Treatment Requested.

 
TRANSFEREES OF PRODUCTS INCORPORATING OR MADE BY USE OF INVENTIONS LICENSED UNDER THIS AGREEMENT. NEITHER PARTY SHALL BE LIABLE FOR ANY CONSEQUENTIAL, INDIRECT OR SPECIAL DAMAGES ARISING OUT OF
THIS AGREEMENT. 
 Section 6 Record Keeping; Accounting 

6.1 Licensee and its Sublicensee(s) shall keep books and records sufficiently to verify the accuracy and completeness of Licensee’s and
its Sublicensee(s)’s accounting, including without limitation, inventory, purchase and invoice records, manufacturing records, sales analysis, general ledgers, financial statements, and tax returns relating to the Licensed Products. Licensee
and its Sublicensee(s) shall preserve these books and records for at least [*] after they are created or as required by federal law, both during and after the term of this Agreement. 

6.2 Licensee shall take all steps necessary so that UFRF may, within [*] of its written request, but no more than [*], audit, review and copy
such of Licensee’s or Sublicensee’s books and records at a single United States location as may be reasonably necessary to verify the accuracy of the royalty reports hereunder for any year ending not more than [*] prior to the date of such
request and which have not previously been audited under this Section 6.2. The review may be performed by any attorneys or accountants designated by UFRF upon reasonable notice and during regular business hours. If a deficiency with regard to
any payment is determined, Licensee and its Sublicensee(s) shall pay the deficiency along with applicable interest as described in Subsection 6.4(a) within [*] of receiving notice. If a payment deficiency for a calendar year exceeds [*] percent
([*]%) of amounts paid for that year, then Licensee or its Sublicensee(s) shall pay UFRF’s out-of-pocket expenses incurred with respect to the review. 

6.3 At any time during the term of this agreement but no more than [*], UFRF may request in writing that Licensee verify the calculation of any
past payments owed to UFRF through the means of a self-audit for any year ending not more than [*] prior to the date of such request and which have not previously been audited under Section 6.2 or this Section 6.3. Within [*] of the
request, Licensee shall complete a self-audit of its books and records to verify the accuracy and completeness of the payments owed. Within [*] of the completion of the self-audit, Licensee shall submit to UFRF a report detailing the findings of the
self-audit and the manner in which it was conducted in order to verify the accuracy and completeness of the payments owed. If Licensee has determined through its self-audit that there is any payment deficiency, Licensee shall pay UFRF the deficiency
along with applicable interest under Subsection 6.4(a) with the submission of the self-audit report to UFRF. 
 6.4 Accounting for
Payments. 
 (a) Any amounts which remain unpaid after the date they are due to UFRF under this Section 6,
Section 7 or any other provision of this Agreement accrue interest from the due date at the rate of [*] percent ([*]%) per month. This interest provision is not a grant of permission for any payment delays. Licensee is responsible for repayment
to UFRF of any attorney, collection agency, and other out-of-pocket expenses to collect overdue payments. 

  

					
		  	Page 9 of 25	  	*Confidential Treatment Requested.

 (b) Except as otherwise directed, Licensee shall pay all amounts owing to UFRF
under this Agreement in United States dollars at the following address: 
 University of Florida Research Foundation, Incorporated 

228 Grinter Hall, PO Box 115500 

Gainesville, Florida 32611-5500 

Attention: Business Manager 

Licensee shall convert all monies owing in currencies other than United States dollars at the rate shown in the Federal Reserve Noon
Valuation—Value of Foreign Currencies on the day preceding the payment due date. 
 (c) On the date of each payment to
UFRF, Licensee shall include on all accounting statements a written representation signed by an executive officer of Licensee that states that, to the best of such officer’s knowledge, the statements are true, accurate, and fairly represent all
amounts payable to UFRF pursuant to this Agreement. Licensee shall provide accounting on a per-country and product line, model or trade name basis and shall summarize them on the form shown in Appendix D–UFRF Royalty Report. 

(d) If no payment is owed to UFRF, Licensee shall supply an accounting demonstrating that fact to UFRF. 

(e) Licensee shall be entitled to deduct from the royalty payments otherwise due to UFRF hereunder the amount of any
withholding taxes, value-added taxes or other taxes, levies or charges which may be imposed on UFRF by any government or political subdivision with respect to such royalty payments that are required to be withheld by Licensee. Licensee shall pay to
the appropriate governmental authority on behalf of UFRF such taxes, levies or charges that are withheld. Licensee shall use reasonable efforts to take such action as may be reasonably requested by UFRF, and at UFRF’s cost, to minimize any such
taxes, levies or charges required to be withheld on behalf of UFRF by Licensee. Licensee promptly shall deliver to UFRF proof of payment of all such taxes, levies and other charges, together with copies of all communications from or with such
governmental authority with respect directly related thereto. Licensee is responsible for all wire/bank fees associated with all payments due to UFRF pursuant to this Agreement. 

Section 7 Patent Prosecution 
 7.1
UFRF shall file, prosecute, and maintain the Patent Rights using counsel of its choice, subject to customary consultation. UFRF shall provide Licensee with copies of all documents sent to and received from the United States Patent and Trademark
Office and foreign patent offices relating to Patent Rights. Licensee shall keep those documents confidential subject to the terms of Section 17 . 

7.2 Licensee shall pay UFRF [*] dollars ($[*]), within [*] of the Effective Date to reimburse expenses associated with preparation, filing,
prosecution, issuance, maintenance, defense, and reporting of the Patent Rights prior to the Effective Date. (NOTE: the above referenced dollar amount in this Section 7.2 is subject to change, as UFRF may not have received all related patent
prosecution expense invoices from the law firm at the time of license negotiation.) 

  

					
		  	Page 10 of 25	  	*Confidential Treatment Requested.

 7.3 UFRF will solicit input from Licensee regarding (a) actions to be taken in connection
with the Patent Rights, and (b) fees, annuities, costs and expenses to be incurred in connection therewith. UFRF will submit, or will cause to be submitted to Licensee all correspondence or other materials related to the preparation, filing,
prosecution (including interferences and oppositions), issuance, maintenance and reporting of the Patent Rights for Licensee’s review and comment prior to any filing or other submission thereof, and UFRF will implement any reasonable comments
provided by Licensee or Licensee’s counsel provided that such comments are not considered by UFRF to be detrimental to UFRF’s interests. If Licensee fails to provide comments regarding actions to be taken, submissions or payment of fees,
annuities, or other costs or expenses within [*] of the date of UFRF’s submission thereof to Licensee then UFRF will assume Licensee has no comments. Licensee shall pay all costs and expenses incurred by UFRF related to the preparation, filing,
prosecution (including interferences and oppositions), issuance, maintenance and reporting of the Patent Rights that were not reimbursed pursuant to Section 7.2 within [*] of receipt of an invoice from UFRF. Licensee shall keep UFRF fully
apprised of the “small entity” status of Licensee and all Sublicensees with respect to United States and applicable foreign patent laws. Licensee shall inform UFRF of any changes in writing of the small entity status within [*] of any
change. 
 7.4 Licensee may elect upon [*] prior written notice to decline to reimburse UFRF for patent expenses for any Patent Right in any
particular country or jurisdiction. In that case, the license granted to Licensee by this Agreement with respect to that Patent Right terminates after the [*] in that country or jurisdiction. Notwithstanding anything to the contrary in this
Agreement, Licensee shall file and maintain the Patent Rights in the following countries: United States, Europe, Canada, Australia, and Japan. 

Section 8 Infringement and Invalidity 

8.1 Licensee shall inform UFRF, and similarly UFRF shall inform Licensee, promptly in writing of any alleged infringement of the Patent Rights
in the Licensed Field and Licensed Territory by a third party and of any available evidence of the alleged infringement. 
 8.2 Licensee may,
but is not obligated to, prosecute at its own expense any alleged infringement of the Patent Rights in the Licensed Field and Licensed Territory, and during the term of this Agreement, it shall have the first right to do so. UFRF will not prosecute
or take any other enforcement-related steps with respect to any such infringements of the Patent Rights except as is provided in Section 8.3. If Licensee prosecutes any infringement, UFRF agrees that Licensee may include UFRF as a party
plaintiff in any infringement suit without expense to UFRF. Licensee shall apply any recovery of damages first in satisfaction of any unreimbursed expenses and legal fees of Licensee relating to the suit and enforcement-related steps related to or
preparatory for such suit, and next toward reimbursement of UFRF for any legal fees and unreimbursed expenses born by UFRF pursuant to Section 8.5 or otherwise at Licensee’s request. If there is any remaining recovery of damages (the
“Balance”), Licensee will pay UFRF a portion thereof, determined according to Table 4.7(b) as if the Balance were fees or payments in consideration for rights granted under a Sublicense entered into at the date the final, non-appealable
judgment was entered (or appeals 

  

					
		  	Page 11 of 25	  	*Confidential Treatment Requested.

 
thereof were exhausted) in connection with such action. Licensee may not enter any settlement, consent judgment, or other voluntary final disposition of the suit without the prior, written
consent of UFRF, which consent UFRF may not unreasonably withhold. Licensee shall indemnify UFRF against any order for costs that may be made against UFRF in the proceedings. 

8.3 If within [*] after notice by either Party to the other of alleged infringement in the Licensed Field and Licensed Territory, or such
earlier time as is necessary to preserve UFRF’s rights, Licensee is unsuccessful in persuading the alleged infringer to desist, has not brought an infringement action against the alleged infringer (unless, and only so long as, Licensee has, as
part of its enforcement strategy, reasonable grounds supporting a delay by Licensee in bringing such action against a particular alleged infringer or infringers, and Licensee so notifies UFRF and provided UFRF’s rights against such infringer
are preserved), or notifies UFRF of its intention not to bring suit against the alleged infringer, then, and in those events only, UFRF may but is not obligated to prosecute at its own expense such alleged infringement of the Patent Rights. UFRF may
use the name of Licensee as party plaintiff in the infringement action without expense to Licensee. If UFRF undertakes the enforcement of the Patent Rights by litigation, UFRF shall apply any recovery of damages first in satisfaction of any
unreimbursed expenses and legal fees of UFRF relating to the suit and next toward reimbursement of Licensee for any legal fees and unreimbursed expenses born by Licensee at UFRF’s request. UFRF will keep any remaining balance. 

8.4 If a declaratory judgment action is brought against UFRF or Licensee by a third party alleging invalidity, unpatentability, or
unenforceability of any of the Patent Rights, and either 
 (i) such action is brought as part of or in connection with any prosecution of an
alleged infringement or any other enforcement-related steps of Licensee pursuant to Section 8.2; or 
 (ii) Licensee is then the sole
licensee of the Patent Rights, 
 then Licensee shall within [*] after commencement of the action take over the sole defense of the action at
its own expense, subject to Sections 8.5 and 8.6. 
 8.5 If Licensee undertakes the enforcement or defense of the Patent Rights by
litigation, UFRF may voluntarily join the litigation, represented by its own counsel at its own expense. Licensee shall apply any recovery of damages first in satisfaction of any unreimbursed expenses and legal fees of Licensee relating to the suit
and next toward reimbursement of UFRF for any legal fees and unreimbursed expenses. Licensee and UFRF shall divide the balance remaining from any recovery as set forth in Section 8.2. 

8.6 In any suit in which either party is involved to enforce or defend the Patent Rights pursuant to this Agreement, the other party shall, at
the request and expense of the party initiating the suit, cooperate in all respects and, to the extent possible, have its employees testify when requested and make available relevant records, papers, information, samples, specimens, and the like.

  

					
		  	Page 12 of 25	  	*Confidential Treatment Requested.

 8.7 If Licensee brings a Patent Challenge against UFRF, unless UFRF terminates this Agreement
pursuant to Section 9.4, Licensee shall continue to pay royalties and make other payments pursuant to this Agreement with respect to such claim(s) as if the contest were not underway until the claim(s) are adjudicated invalid or unenforceable
by a court of last resort. 
 Section 9 Term and Termination 

9.1 The term of this Agreement begins on the Effective Date and continues until it expires by its terms or is terminated as set forth below.

 9.2 Licensee may terminate this Agreement at any time by giving at least [*] prior written notice to UFRF. Licensee shall include a
statement of the reasons for termination in the notice. 
 9.3 UFRF may terminate this Agreement by giving Licensee at least [*] written
notice if Licensee: 
 (a) is delinquent on any report, payment or required documents as specified in any section of this
Agreement; 
 (b) is in breach of Section 3.1(c); 

(c) is in breach of any provision of this Agreement; 

(d) provides any false report; 

(e) goes into bankruptcy, liquidation or proposes having a receiver control any of its assets; 

(f) violates any laws or regulations applicable to development or commercialization of Licensed Products; 

(g) ceases to carry on its business pertaining to Patent Rights; or 

(h) ceases for more than two (2) consecutive calendar quarters to make payments of earned royalties under Sections 4.4 or
4.7 once begun. 
 Termination under this Section 9.3 takes effect [*] after written notice by UFRF, unless Licensee remedies the
problem in that [*] period, and provided, however, that if Licensee disputes in good faith that the claimed breach exists, such [*] period will not start to run until such dispute has been resolved in accordance with Section 11. 

9.4 If Licensee or any of its Affiliates brings a Patent Challenge against UFRF or actively assists others in bringing or maintaining a Patent
Challenge against UFRF (except as required under a court order or subpoena), then UFRF may immediately terminate this Agreement. If a Sublicensee brings a Patent Challenge or actively assists another party in bringing or 

  

					
		  	Page 13 of 25	  	*Confidential Treatment Requested.

 
maintaining a Patent Challenge (except as required under a court order or subpoena), then UFRF may send a written demand to Licensee to terminate the Sublicense. If Licensee fails to terminate
the Sublicense within [*] after UFRF duly makes such a demand, UFRF may immediately terminate this Agreement. 
 9.5 Termination of this
Agreement for any reason does not release either party from any obligation that matured prior to the effective date of termination. Licensee remains obligated to provide an accounting for and to pay royalties earned. Licensee may prorate any minimum
royalties that are due as of the date of termination by the number of days elapsed in the applicable calendar year. Licensee and its Sublicensees may, however, during the [*] after the effective date of termination, sell all Licensed Products that
are in inventory and complete and sell Licensed Products that are in the process of manufacture , provided that Licensee provides an accounting for and pays all earned royalties and other payments that are due under the terms of the Agreement. 

9.6 Upon expiration or termination of the Agreement for any reason, the following sections of the License Agreement remain in force as
non-cancelable obligations: 
  

	 	•	 	Section 6 Record Keeping; Accounting 

  

	 	•	 	Section 9.5 Effect of Termination 

  

	 	•	 	Section 12 Indemnification; Insurance 

  

	 	•	 	Section 13 Use of Names 

  

	 	•	 	Section 14 Miscellaneous 

  

	 	•	 	Section 17 Confidentiality 

 9.7 Licensee shall deliver to UFRF, within [*] after the date
of termination of this Agreement, complete and un-redacted copies of all documentation prepared for or submitted for all regulatory approvals of Licensed Products. 

Section 10 Assignability 
 10.1 This
Agreement may not be transferred or assigned by Licensee except with the prior written consent of UFRF, not to be unreasonably withheld. Notwithstanding the foregoing, written notice shall be provided but no such consent shall be required in the
event of any transfer or assignment by operation of law in connection with a merger or reorganization or consolidation of Licensee or a sale of all or substantially all of the assets of Licensee. Any attempted assignment in contravention of this
Section 10.1 is void. 
 10.2 The new assignee shall assume all responsibilities under this Agreement and agree in writing to UFRF to be
bound by this Agreement. 
 Section 11 Dispute Resolution 

11.1 Mandatory Procedures. Before either party intends to file a lawsuit against the other with respect to any matter in connection with
this Agreement, except with regard to any payments made or due under this Agreement, it shall first comply with the procedures set forth in this Section 11, other than for injunctive relief to enforce the provisions of this Section 11.

  

					
		  	Page 14 of 25	  	*Confidential Treatment Requested.

 (a) When a party intends to invoke the procedures set forth in this
Section 11, it shall provide written notice to the other party. Within [*] after the date of that notice, senior representatives of the parties shall engage in good faith negotiations at a mutually convenient location to resolve the dispute. In
the case of UFRF, that representative is the Director of Technology Licensing. In the case of Licensee, that representative is the VP of Corporate Development. 

(b) If the parties fail to meet within the time period set forth in Section 11(a) or if either party subsequently
determines that negotiations between the representatives of the parties are at an impasse, the party declaring that the negotiations are at an impasse shall give notice to the other party stating with particularity the issues that remain in dispute.

 (c) Not more than [*] after the notice of issues under Section 11(b), the President of UFRF and the Chief Executive
Officer of the Licensee shall meet and engage in good faith negotiations at a mutually convenient location to resolve the dispute. 
 11.2
Failure to Resolve Dispute. If (a) any issue is not resolved at the meeting of the President and Chief Executive Officer within [*] after they first meet or (b) there is a dispute regarding payments made or due under this Agreement,
either party may file appropriate administrative or judicial proceedings with respect to the issue in dispute. The parties agree to consider in good faith any proposals to address issues through alternative dispute resolution. 

Section 12 Indemnification; Insurance 

12.1 Licensee and Sublicensee(s) shall, at all times during the term of this Agreement and thereafter, indemnify, defend and hold UFRF, the
Florida Board of Governors, the University of Florida Board of Trustees, the University of Florida, and each of their directors, trustees, officers, employees, and agents, the Investigator, and the inventors of the Patent Rights, regardless of
whether the inventors are employed by the University of Florida at the time of the claim, harmless against all claims and liabilities, including legal expenses and reasonable attorneys’ fees, arising from a third party claim, arising out of the
death of or injury to any person or persons or out of any damage to property and against any other third party claim, proceeding, demand, expense and liability resulting from the development, production, manufacture, sale, use, lease, consumption,
marketing, or advertisement of Licensed Products; except to the extent such claims result from the gross negligence, willful misconduct or breach of applicable law by any indemnitee. UFRF shall give Licensee prompt notice of any such claim.
Notwithstanding the above, UFRF at all times reserves the right to retain counsel of its own to defend the interests of UFRF, the Florida Board of Governors, the University of Florida Board of Trustees, the University of Florida, and the
inventor(s). UFRF shall give Licensee prompt notice of any such claim. 
 12.2 Licensee warrants that it now maintains and will continue to
maintain liability insurance coverage appropriate to the risk involved in developing, producing, manufacturing, conducting clinical trials for, selling, marketing, using, leasing, consuming, or advertising the products and processes that are subject
to this Agreement and that the insurance coverage lists UFRF, the Florida Board of Governors, the University of Florida Board of Trustees, the University 

  

					
		  	Page 15 of 25	  	*Confidential Treatment Requested.

 
of Florida, the Investigator, and the inventors of the Patent Rights as additional insureds. Within [*] after the execution of this Agreement and thereafter annually between January 1 and
January 31 of each year, Licensee will present evidence to UFRF that the coverage is being maintained. In addition, Licensee shall provide UFRF with at least [*] prior written notice of any change in or cancellation of the insurance coverage.

 Section 13 Use of Names 

Licensee and its Sublicensee(s) may not use the names or logos of UFRF or the University of Florida, nor of any of either institution’s
employees, agents, or affiliates, nor the name of any inventor of Patent Rights or Know-How, nor any adaptation of those names, in any promotional, advertising or marketing materials or any other form of publicity, or to suggest any endorsement by
these entities or individuals, without the prior written approval of UFRF in each case. 
 Section 14 Miscellaneous 

14.1 Governing Law. This Agreement shall be governed and construed in accordance with the internal laws of the State of Florida without
regard to its conflict of laws provisions, and venue for all claims or other causes of action arising out of this Agreement is Gainesville, Florida. 

14.2 Independent Contractors. The parties are independent contractors and not joint venturers or partners. 

14.3 Integration. This Agreement constitutes the full understanding between the parties with reference to its subject matter, and no
statements or agreements by the parties, whether oral or in writing, may modify the terms of this Agreement. Neither party may claim any amendment, modification, or release from any provisions of this Agreement, unless the mutual agreement is in
writing and signed by both parties. 
 14.4 No Security Interest. Licensee may not encumber or otherwise grant a security interest in
any of the rights granted under this Agreement to any third party. 
 14.5 Laws and Regulations. Licensee shall comply with all local,
state, federal, and international laws and regulations that are applicable to the development, manufacture, use, and sale of Licensed Products, including: 

(a) Licensee acknowledges that it is subject to and agrees to abide by United States laws and regulations (including the Export
Administration Act of 1979 and Arms Export Control Act) controlling the export of technical data, computer software, laboratory prototypes, biological material, and other commodities. The transfer of those items may require a license from the
cognizant agency of the United States Government or written assurances by Licensee that it will not export items to certain foreign countries or persons without prior approval by that agency. UFRF neither represents that a license is or is not
required nor that, if required, it will be issued. 

  

					
		  	Page 16 of 25	  	*Confidential Treatment Requested.

 (b) Licensee shall obtain all necessary approvals from the United States
Food & Drug Administration, Environmental Protection Agency, Department of Agriculture and any similar governmental authorities of foreign jurisdictions in which Licensee intends to make, use, or sell Licensed Products or perform licensed
processes. 
 14.6 Force Majeure. Neither party is responsible for default, delay, or failure to perform, if such default, delay or
failure to perform is due to causes beyond the party’s reasonable control, including, but not limited to, strikes, lockouts, inactions of governmental authorities, war, fire, hurricane or other natural disaster, provided that the nonperforming
party uses commercially reasonable efforts to avoid or remove those causes of nonperformance and continues performance under this Agreement with reasonable dispatch when the causes are removed. In the event of a default, delay or failure to perform
described in this Section 14.6, any date or times by which either party is scheduled to perform is extended automatically for a time equal to the time lost by reason of the excused default, delay or failure to perform. 

14.7 Severability. If any provision of this Agreement shall be held invalid, illegal or unenforceable, such provision shall be enforced
to the maximum extent permitted by law and the parties’ fundamental intentions hereunder, and the remaining provisions shall not be affected or impaired. 

Section 15 Notices 
 The parties
shall provide any notice required to be given pursuant to this Agreement in writing to the addresses listed in this Section 15. Notice is effective on the day it is delivered personally with written receipt from an authorized signatory, on the
second day after the day on which the notice has been delivered for next day delivery prepaid to a nationally recognized courier service, on the fifth business day following deposit in the United States mail if sent certified or registered mail,
(return receipt acknowledgement is not required to certify delivery). 
  

			
	 If to UFRF:
  

President
 University of Florida Research Foundation,
Incorporated
 223 Grinter Hall University of Florida
 P. O. Box
115500
 Gainesville, FL 32611-5500
  

with a copy to:
  

Office of Technology Licensing University of Florida
 Attn:
Director (Rm. 112)
 747 SW 2nd Avenue
 Post Office Box
115575
 Gainesville, Florida 32611-5575
	 	 If to Licensee:
  

Attn: CEO
 Audentes Therapeutics, Inc.

101 Montgomery St, Suite 2650
 San Francisco, CA 94104

 
 with a copy to:

  

					
		  	Page 17 of 25	  	

 Section 16 United States Government Interests 

The United States Government has funded Grant Nos. [*] and [*] during the course of or under which certain of the inventions of the Patent
Rights were conceived or reduced to practice. The United States Government is entitled under the provisions of 35 U.S.C. §202-212 and applicable regulations to a non-exclusive, nontransferable, irrevocable, paid-up license to practice or have
practiced those inventions for or on behalf of the United States throughout the world. Any license granted to Licensee in this Agreement is subject to that license. If any invention claimed in the Patent Rights was funded by the United States
Government, Licensee agrees that Licensed Products that are used or sold in the United States will be manufactured substantially in the United States. 

Section 17 Confidentiality 
 (a)
Unless required by Florida Law, the parties (a) may only use each other’s Confidential Information (as defined below) as necessary to perform the obligations or exercise the rights set forth in this Agreement (b) may not disclose the
other’s Confidential Information to any third party, and (c) shall protect each other’s Confidential Information with the same degree of care that they exercise with their own Confidential Information but in no event less than a
reasonable degree of care. For the purposes of this Agreement, “Confidential Information” means the terms of this Agreement and information disclosed by one party to the other that is marked “confidential” by the
disclosing party or that is confirmed in writing within [*] after verbal disclosure. Confidential Information does not include information that (i) is publicly known ; (ii) is already known or independently developed without use of
the Confidential Information as shown by written records; (iii) is disclosed by a third party having no known obligation of confidentiality with respect to the Confidential Information; or (iv) is required to be disclosed to comply with
applicable laws or regulations or with a court or administrative order. These confidentiality obligations remain effective for [*] after disclosure of the Confidential Information. The parties acknowledge and agree that the Vector Plasmid’s
sequence is publicly known and therefore not protected under this Section 17. 
 (b) Each recipient may use or disclose Confidential
Information disclosed to it by the other Party or the terms of this Agreement to the extent such use or disclosure is reasonably necessary in: (i) prosecuting or defending, or complying with discovery requests in, legal or administrative
actions, provided that recipient shall provide the other Party with prompt notice of such requirement, so that the other Party can file a motion for a protective order or otherwise seek whatever legal relief it deems desirable or appropriate to
protect its interest in the Confidential Information, (ii) complying with any applicable law, order, rule or regulation of any court or governmental body or regulatory agency or otherwise submitting information to tax or other governmental
authorities, and (iii) filings under applicable securities laws or regulations or per the rules of any securities exchange or similar organization. 

  

					
		  	Page 18 of 25	  	*Confidential Treatment Requested.

 (c) Each recipient may use or disclose Confidential Information disclosed to it
by the other Party or the terms of this Agreement (i) to potential and actual sublicensees, acquirers, investors, underwriters and lenders, subject to reasonable non-use and non-disclosure requirements and (ii) to its and its
Affiliates’ respective employees, directors, contractors, legal advisors, accountants, and financial advisors, in each case provided such individuals are subject to reasonable non-use and non-disclosure requirements no less stringent than those
the recipient takes to protect its own confidential and/or proprietary material of a similar nature. 
 Section 18 University Rules and Regulations

 Licensee understands and agrees that University of Florida personnel who are engaged by Licensee, whether as consultants, employees,
or otherwise or who possess a material financial interest in Licensee are subject to the University of Florida’s rules regarding outside activities and financial interests set forth in University of Florida Regulation 1.011, the University of
Florida’s Intellectual Property Policy, and an associated monitoring plan which addresses conflicts of interests . Any term of an agreement between Licensee and University of Florida personnel which seeks to vary or override the
personnel’s obligations to the University of Florida may not be enforced without the express written consent of an individual authorized to vary or waive such obligations on behalf of the University of Florida Board of Trustees and UFRF.
Furthermore, should an interest of Licensee conflict with the interests of the University of Florida, University of Florida personnel are obligated to resolve those conflicts according to the rules, guidelines, and policies of the University of
Florida. 
 Section 19 Contract Formation and Authority 

19.1 The submission of this Agreement is not an offer, and this document is effective and binding only upon the execution by duly authorized
representatives of both Licensee and UFRF. Copies of this Agreement that have not been executed and delivered by both UFRF and Licensee do not evidence an agreement between the parties. UFRF may terminate this Agreement without the requirement of
any notice to Licensee, if UFRF does not receive the License Issue Fee, as applicable, within [*] of the Effective Date. 
 19.2 UFRF and
Licensee hereby warrant and represent that the persons signing this Agreement have authority to execute this Agreement on behalf of the party for whom they have signed. 

  

					
		  	Page 19 of 25	  	*Confidential Treatment Requested.

 The parties have duly executed this Agreement on the dates indicated below. 

 

									
	UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED	 		 	Audentes Therapeutics, Inc.
				
	/s/ David L. Day	 		 	By:	 	/s/ Matthew R. Patterson
	 David L. Day
 Director of Technology
Licensing
	 		 		 	 Matthew R. Patterson
 President and Chief
Executive Officer

				
	Date: 8/4, 2015	 		 	Date:	 	8/4, 2015

  

					
		  	Page 20 of 25	  	

 Appendix A – Patent Rights and Know-How 

Patent Rights 
 [*] 

[*] 
 [*] 

Know-How 
  

			
	[*]
	Type of Know-How	  	
	[*]	  	[*]
	[*]	  	[*]

 Information related to development of AAV technology for Pompe disease. The below table includes published materials or
already available study reports. 
 [*] 
 Further information
related to development of AAV technology for Pompe disease. 
 [*] 

Materials, records, and assay results required for manufacture of AAV for Pompe, as well as the vector construct itself, controlled by UFL, as follows: 

[*] 

  

					
		  	Page 21 of 25	  	*Confidential Treatment Requested.

 Appendix B—Development Plan 

[*] 

  

					
		  	Page 22 of 25	  	*Confidential Treatment Requested.

 Appendix C Development Report 

[*] 

  

					
		  	Page 23 of 25	  	*Confidential Treatment Requested.

 Appendix D—UFRF Royalty Report 

[*] 

  

					
		  	Page 24 of 25	  	*Confidential Treatment Requested.

 Appendix E – Milestones 
  

			
	 Event
	  	Date
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]

  

					
		  	Page 25 of 25	  	*Confidential Treatment Requested.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}]]